| Title: |
Targeting STEAP1 as an anticancer strategy |
| Authors: |
Hajime Nakamura, Yohei Arihara, Kohichi Takada |
| Source: |
Frontiers in Oncology, Vol 13 (2023) |
| Publisher Information: |
Frontiers Media S.A., 2023. |
| Publication Year: |
2023 |
| Collection: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: |
STEAP1, antibody therapy, CAR-T therapy, cancer vaccine, anticancer strategies, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: |
Although the six-transmembrane epithelial antigen of prostate 1 (STEAP1) was first identified in advanced prostate cancer, its overexpression is recognized in multiple types of cancer and associated with a poor prognosis. STEAP1 is now drawing attention as a promising therapeutic target because of its tumor specificity and membrane-bound localization. The clinical efficacy of an antibody-drug conjugate targeting STEAP1 in metastatic, castration-resistant, prostate cancer was demonstrated in a phase 1 trial. Furthermore, growing evidence suggests that STEAP1 is an attractive target for immunotherapies such as chimeric antigen receptor-T cell therapy. In this review, we summarize the oncogenic functions of STEAP1 by cancer type. This review also provides new insights into the development of new anticancer strategies targeting STEAP1. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2234-943X |
| Relation: |
https://www.frontiersin.org/articles/10.3389/fonc.2023.1285661/full; https://doaj.org/toc/2234-943X |
| DOI: |
10.3389/fonc.2023.1285661 |
| Access URL: |
https://doaj.org/article/a69def6b55f844a0accb364867bf0331 |
| Accession Number: |
edsdoj.69def6b55f844a0accb364867bf0331 |
| Database: |
Directory of Open Access Journals |
